Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Department of Community Health Sciences, University of Calgary.
Eur J Endocrinol. 2021 Jan;184(1):19-28. doi: 10.1530/EJE-20-0628.
Despite the significant morbidity and mortality associated with pheochromocytoma and paraganglioma, little is known about their epidemiology. The primary objective was to determine the incidence of pheochromocytoma and paraganglioma in an ethnically diverse population. A secondary objective was to develop and validate algorithms for case detection using laboratory and administrative data.
Population-based cohort study in Alberta, Canada from 2012 to 2019.
Patients with pheochromocytoma or paraganglioma were identified using linked administrative databases and clinical records. Annual incidence rates per 100 000 people were calculated and stratified according to age and sex. Algorithms to identify pheochromocytoma and paraganglioma, based on laboratory and administrative data, were evaluated.
A total of 239 patients with pheochromocytoma or paraganglioma (collectively with 251 tumors) were identified from a population of 5 196 368 people over a period of 7 years. The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year. The frequency of pheochromocytoma and paraganglioma increased with age and was highest in individuals aged 60-79 years (8.85 and 14.68 cases per 100 000 people per year for males and females, respectively). An algorithm based on laboratory data (metanephrine >two-fold or normetanephrine >three-fold higher than the upper limit of normal) closely approximated the true frequency of pheochromocytoma and paraganglioma with an estimated incidence of 0.54 cases per 100 000 people per year.
The incidence of pheochromocytoma and paraganglioma in an unselected population of western Canada was unexpectedly higher than rates reported from other areas of the world.
尽管嗜铬细胞瘤和副神经节瘤与显著的发病率和死亡率相关,但人们对其流行病学知之甚少。主要目的是确定在种族多样化的人群中嗜铬细胞瘤和副神经节瘤的发病率。次要目标是开发和验证使用实验室和行政数据进行病例检测的算法。
2012 年至 2019 年在加拿大艾伯塔省进行的基于人群的队列研究。
通过链接的行政数据库和临床记录确定患有嗜铬细胞瘤或副神经节瘤的患者。计算每 100000 人年的发病率,并按年龄和性别分层。评估基于实验室和行政数据的识别嗜铬细胞瘤和副神经节瘤的算法。
在 7 年期间,从 5196368 人中发现了 239 例患有嗜铬细胞瘤或副神经节瘤(共 251 例肿瘤)的患者。嗜铬细胞瘤或副神经节瘤的总发病率为每年每 100000 人 0.66 例。嗜铬细胞瘤和副神经节瘤的频率随年龄增加而增加,在 60-79 岁的个体中最高(男性和女性分别为每年每 100000 人 8.85 和 14.68 例)。基于实验室数据(间甲肾上腺素>两倍或去甲肾上腺素>三倍高于正常值上限)的算法与嗜铬细胞瘤和副神经节瘤的真实频率非常接近,估计发病率为每年每 100000 人 0.54 例。
在加拿大西部一个未选择的人群中,嗜铬细胞瘤和副神经节瘤的发病率出人意料地高于世界其他地区的报告率。